Effects of natalizumab treatment on Foxp3+ T regulatory cells.
PLoS ONE, 2008 BackgroundNatalizumab, a monoclonal humanized antibody targeting the alpha-4 chain of very late activation antigen 4 (VLA-4) exerts impressive therapeutic effects in patients with relapsing-remitting multiple sclerosis. Our objective was to study impacts
Max-Philipp Stenner +6 more
doaj +1 more source
JC virus-DNA detection is associated with CD8 fffector accumulation in peripheral blood of patients with multiple sclerosis under natalizumab treatment, independently from JC virus serostatus [PDF]
, 2018 Although natalizumab (anti-α4 integrin) represents an effective therapy for relapsing remitting multiple sclerosis (RRMS), it is associated with an increased risk of developing progressive multifocal leukoencephalopathy (PML), caused by the polyomavirus ...
Anzivino, Elena +16 more
core +3 more sources
Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers
Arquivos de Neuro-Psiquiatria, 2015 Objective Analyze the demographics, clinical characteristics, efficacy and safety of natalizumab treatment in Brazilian patients with multiple sclerosis (MS) followed up for at least 12 months, in two tertiary MS care centers in São Paulo.Method We ...
Enedina Maria Lobato de Oliveira +5 more
doaj +1 more source
Journal of Neurology, 2022 Exit strategy after natalizumab cessation in multiple sclerosis (MS) is a crucial point because the risk of disease reactivation is high during this period.
K. Bigaut +9 more
semanticscholar +1 more source
Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis. [PDF]
PLoS ONE, 2012 Natalizumab is a recombinant monoclonal antibody raised against integrin alpha-4 (CD49d). It is approved for the treatment of patients with multiple sclerosis (MS), a chronic inflammatory autoimmune disease of the CNS. While having shown high therapeutic
Thomas F Benkert +7 more
doaj +1 more source
Neurofilament Light Chain Concentration in the Prediction of Treatment Response in Multiple Sclerosis. [PDF]
Eur J NeurolThis graphical abstract shows that serum NfL was evaluated alongside clinicodemographic variables that were reduced using principal component analysis (PCA). These components were then incorporated into a combined prognostic model. The addition of serum NfL did not result in any significant improvement in prognostic accuracy in the pooled cohort ...
Moradi N +18 more
europepmc +2 more sources
Inflammatory Activity on Natalizumab Predicts Short-term but not Long-term Disability in Multiple Sclerosis [PDF]
, 2017 BACKGROUND: In people with multiple sclerosis treated with interferon-beta or glatiramer acetate, new MRI lesions and relapses during the first year of treatment predict a poor prognosis.
Dahdaleh, S +5 more
core +1 more source
Neurology, 2021 Objective To investigate pregnancy-related disease activity in a contemporary multiple sclerosis (MS) cohort. Methods Using data from the MSBase Registry, we included pregnancies conceived after December 31, 2010, in women with relapsing-remitting MS or ...
W. Yeh +45 more
semanticscholar +1 more source
Piloting home infusions of Tysabri (natalizumab): a randomised crossover trial
International Journal of Integrated Care, 2019 We developed a new model of care for home infusions of natalizumab for people with multiple sclerosis. The new model of care was then tested in a pilot study comparing home infusions of natalizumab with usual care (attendance in an ambulatory care day ...
Tim Schultz +8 more
doaj +1 more source
Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis? [PDF]
PLoS ONE, 2017 Progressive multifocal leukoencephalopathy (PML) is one of the major risks of natalizumab therapy. Despite introduction of the currently employed PML risk stratification algorithm, the incidence of natalizumab-associated PML cases is not decreasing.We ...
Julia Krämer +6 more
doaj +1 more source